Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Cooperative Research and Development Agreement
View Prospective Grant of Exclusive License: Vaccines Against Rotavirus Disease Only written comments and/or applications for a license which are received by NIH on or before April 15, 2003 will be considered.
View Prospective Grant of Exclusive License: Novel Vaccinia Virus Vector for the Treatment of Human Cancers Only written comments and/or license applications which are received by the National Institutes of Health on or before April 14, 2003, will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: “Interleukin-2 Receptor and Applications Thereof” Only written comments and/or license applications which are received by the National Institutes of Health on or before April 7, 2003 will be considered.
View Prospective Grant of Exclusive License: “Spatially and Temporal Control of Gene Expression Protein Promoter in Combination with Local Heat” Only written comments and/or license applications which are received by the National Institutes of Health on or before April 7, 2003 will be considered.
View Prospective Grant of Exclusive License: Nucleic Acid Vaccines for Prevention of Flavivirus Infection
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Methods and Compositions for the Promotion of Hair Growth Utilizing Actin Binding Peptides Only written comments and/or license applications which are received by the National Institutes of Health on or before February 24, 2003, will be considered.
View Prospective Grant of Exclusive License: “Coil for Transcranial Magnetic Stimulation” Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before February 7, 2003, will be considered.
View Prospective Grant of Exclusive License: Conjugate Vaccines To Prevent Diseases Caused by Nontypeable Haemophilus Influenzae and Moraxella Catarrhalis, Particularly Otitis Media Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before January 28, 2003 will be considered.
View National Cancer Institute: Chemical Optimization of Molecular-Targeted Anticancer, Antiviral and Antimicrobial Drug Leads Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential CRADA proposals, preferably two pages or less, must be submitted to the NCI. Review of proposals will begin within 90 days from date of this publication and will continue until a suitable collaborator(s) is identified. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.
View Prospective Grant of Exclusive License: Pharmaceutical Methods of Delivering Folic Acid in a Hormonal Replacement or Contraceptive Composition 04/16/1999. Domestic Status: Patent No.: 6,190,693. Issue Date: 02/20/2001.
View Prospective Grant of Co-Exclusive License: “Endotracheal Tube Using Leak Hole To Lower Resistance and Dead Space” Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before December 30, 2002 will be considered.
View Prospective Grant of Exclusive License: “Modulating IL-13 Activity Using Mutated IL-13 Molecules that are Antagonists or Agonists of IL-13”, PCT Application PCT/US00/31044 Only written comments and/or license applications that are received by the National Institutes of Health on or before December 30, 2002 will be considered.
View Prospective Grant of Exclusive License: “Nucleic acid encoding mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers” U.S. Patent 6,152,430, Issued November 28, 2000, and “Mesothelium antigen and methods and kits for targeting it” U.S. Patent 6,083,502, Issued July 4, 2000 Only written comments and/or license applications that are received by the National Institutes of Health on or before December 30, 2002 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Drug and Method for the Therapeutic Treatment of Head and Neck Cancer Only written comments and/or license applications which are received by the National Institutes of Health on or before November 25, 2002, will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Co-Exclusive License: Prophylactic and/or Therapeutic Vaccine Against Pseudomonas Aeruginosa Only written comments and/or applications for a license which are received by NIH on or before November 18, 2002 will be considered.
View Prospective Grant of Exclusive License: “Compositions and Methods for In Vitro Fertilization” Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before November 12, 2002, will be considered.
View Prospective Grant of Exclusive License: “Laser Capture Microdissection (LCM) for Cellular Protein Analysis” Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before November 12, 2002, will be considered.
View Prospective Grant of Exclusive License: Human Papilloma Virus-Like Particles for the Induction of Autoantibodies Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before October 28, 2002 will be considered.
View Prospective Grant of Exclusive License: “P2X7 Receptor Antagonists” Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before October 28, 2002 will be considered.
View Prospective Grant of Exclusive License: “Antiprogestins With Partial Agonist Activity Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before October 28, 2002 will be considered.